Placebo for myositis ossificans

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 27 May 2022: Trial registered, NCT05394116
  2. 21 Nov 2022: Trial started, NCT05394116

The trials

NCT05394116: A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

State
Under way
Phase
Phase 3
People
63 taking part
Started
21 Nov 2022
Primary completion
17 Jul 2025
Arms
Placebo
Results
Posted on the registry
Papers
doi:10.1016/s0140-6736(26)01599-0
  1. 27 May 2022: Trial registered
  2. 21 Nov 2022: Trial started
  3. 17 Nov 2026: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.